clinical trial · NCT02966756
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
AbbVie·phase2·recruiting·n = 110
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Venetoclax
brief summary
This is a Phase 2, open-label, multicenter study, evaluating the efficacy of venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) either in presence of 17p deletion (Cohort 1) or those who have failed a B-receptor signaling pathway inhibitor (BCRI) therapy and who have also failed, or were unable to receive chemoimmunotherapy (CIT) irrespective of 17p status (Cohort 2).
started
Oct 12, 2017
primary completion
May 1, 2029
completion
May 1, 2029
last updated
Dec 24, 2025
official title
A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol